Linked Data API

Show Search Form

Search Results

1124901
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Nusinersen more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15576 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15577 more like this
star this property question first answered
less than 2019-05-17T11:07:46.62Zmore like thismore than 2019-05-17T11:07:46.62Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1124902
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15577 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15576 more like this
star this property question first answered
less than 2019-05-17T11:07:46.673Zmore like thismore than 2019-05-17T11:07:46.673Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1125504
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15599 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15600 more like this
star this property question first answered
less than 2019-05-22T14:50:14.54Zmore like thismore than 2019-05-22T14:50:14.54Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
star this property label Biography information for Baroness Masham of Ilton more like this
1125505
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15600 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15599 more like this
star this property question first answered
less than 2019-05-22T14:50:14.483Zmore like thismore than 2019-05-22T14:50:14.483Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
star this property label Biography information for Baroness Masham of Ilton more like this
1125506
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading HIV Infection: Vaccination more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15601 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-05-22T14:50:46.107Zmore like thismore than 2019-05-22T14:50:46.107Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
1850
star this property label Biography information for Baroness Masham of Ilton more like this
1125517
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Migrant Workers more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to increase the number of NHS staff recruited from EU member states after Brexit. more like this
star this property tabling member printed
Lord Taylor of Warwick more like this
star this property uin HL15612 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The Government recognises the need to be able to recruit effectively from abroad and the Immigration White Paper, <em>The UK’s future skills-based immigration system</em>, published in December 2018, sets out the foundation for a single immigration system, where it is workers’ skills that matter, not where they come from. This system will streamline the high-skilled visa route, by removing the Resident Labour Market Test and the Tier 2 Visa Cap. The Home Office is undertaking a programme of engagement to discuss the proposed measures with colleagues across Government and industry, to develop a future immigration system that works for the whole of the United Kingdom.</p><p>The Government wants to support the National Health Service in expanding international recruitment more widely, as this clearly has a role to play to meeting staffing shortages, especially in the short term. Recruitment of doctors and nurses is the responsibility of individual NHS organisations, a number of which do actively recruit from overseas, including from countries in the European Union. However, we also recognise the need to boost our domestic workforce as well. The NHS Long Term Plan sets out a vital strategic framework to ensure that, over the next 10 years, the NHS will have the staff it needs so that nurses and doctors are working in a supportive culture that allows them to provide the expert compassionate care they are committed to providing. Details of this will be explored more fully in the forthcoming Interim NHS People Plan.</p><p>The Government has taken steps to ensure that EU citizens can continue to come and work in the NHS once we have left the EU. In March 2019, we put in place legislation that ensures the continued recognition of qualifications from EU countries by all professional regulators covering the health and social care sectors. This means that EU citizens will continue to be able to come and practice in the UK once we have left the EU, even if we leave without a deal.</p>
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-05-22T14:54:38.56Zmore like thismore than 2019-05-22T14:54:38.56Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
1796
star this property label Biography information for Lord Taylor of Warwick more like this
1124720
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Idiopathic Pulmonary Fibrosis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) early diagnosis and (b) treatment of idiopathic pulmonary fibrosis. more like this
star this property tabling member constituency Stevenage more like this
star this property tabling member printed
Stephen McPartland more like this
star this property uin 250788 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The United Kingdom Rare Disease Strategy, published in 2013, sets out our commitment to raising awareness about all rare diseases including idiopathic pulmonary fibrosis (IPF) and our strategic vision for improving the lives of all those affected. The Strategy promotes improvements to ensure that people living with a rare disease receive high-quality care.</p><p>The Government recognizes the need for awareness raising and training of health care professionals for rare diseases. This is being taken forward through the work of the UK Rare Diseases Policy Board and NHS England’s Rare Diseases Implementation plan, which commits NHS England to engaging with the Royal College of General Practitioners (GPs) and the Nursing and Midwifery Council on opportunities for GPs and health visitors to recognise and facilitate earlier diagnosis of rare diseases.</p><p>There are limited drug treatment options for IPF and two drugs, Pirfenidone and Nintedanib, are commissioned following National Institute for Health and Care Excellence Technology Appraisals. Alongside this, the Department funds research into rare diseases such as IPF through the National Institute for Health Research (NIHR).</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:35:47.667Zmore like thismore than 2019-05-15T16:35:47.667Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4093
star this property label Biography information for Stephen McPartland more like this
1124918
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251321 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251322 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.547Zmore like thismore than 2019-05-15T16:14:44.547Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124919
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251322 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.61Zmore like thismore than 2019-05-15T16:14:44.61Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124920
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood Diseases: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251323 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.657Zmore like thismore than 2019-05-15T16:14:44.657Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this